Product Details
| Alternative Name: | Lymphocyte activation gene-3, FDC protein, CD223 |
| |
| MW: | ~180kDa (SPS-PAGE, nonreducing), ~80kDa (SPS-PAGE, reducing) |
| |
| Source: | Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of mouse LAG-3 (D1-D4) is fused to the Fc portion of mouse IgG2a (hinge-CH2-CH3). |
| |
| UniProt ID: | Q61790 |
| |
| Concentration: | 0.5mg/ml |
| |
| Formulation: | Liquid. In PBS. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Endotoxin Content: | <1EU/µg purified protein (LAL test; Bio Whittaker). |
| |
| Species reactivity: | Human, Mouse
|
| |
| Specificity: | Binds to human and mouse MHC class II. |
| |
| Biological Activity: | Induces maturation of mouse dendritic cells in vitro. Induces CD4 and CD8 antigen-specific T cells responses when coinjected s.c. in mice, together with the antigen. |
| |
| Applications: | Flow Cytometry
|
| |
| Reconstitution: | Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Scientific Background: | The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice: P. Cappello, et al.; Cancer Res.
63, 2518 (2003),
Abstract;
Full Text
General Literature References
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett.
235, 147 (2006),
Abstract;
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination: F. Triebel; Trends Immunol.
24, 619 (2003),
Abstract;
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo: C. Lienhardt, et al.; Eur. J. Immunol.
32, 1605 (2002),
Abstract;
Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-gamma production: F. Annunziato, et al.; FASEB J.
10, 769 (1996),
Abstract;
